Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
62.24
-2.36 (-3.65%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Corcept Therapeutics Revenue
In the year 2024, Corcept Therapeutics had annual revenue of $675.04M with 39.94% growth. Corcept Therapeutics had revenue of $181.89M in the quarter ending December 31, 2024, with 34.33% growth.
Revenue (ttm)
$675.04M
Revenue Growth
+39.94%
P/S Ratio
9.52
Revenue / Employee
$1,350,080
Employees
500
Market Cap
6.57B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CORT News
- 3 days ago - It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder - Seeking Alpha
- 11 days ago - Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer - Business Wire
- 17 days ago - Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release - Seeking Alpha
- 17 days ago - Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company - Seeking Alpha
- 18 days ago - Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast - Benzinga
- 18 days ago - Corcept's ovarian cancer combination drug meets main goal in late-stage study - Reuters
- 18 days ago - Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 5 weeks ago - Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman, LLC (CORT) Investors to Inquire about Securities Investigation - Accesswire